Comparative Pharmacology
Head-to-head clinical analysis: DEPO ESTRADIOL versus DIETHYLSTILBESTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPO ESTRADIOL versus DIETHYLSTILBESTROL.
DEPO-ESTRADIOL vs DIETHYLSTILBESTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol is an estrogen hormone that binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene transcription and exerting effects such as proliferation of endometrial tissue, regulation of gonadotropin secretion (negative feedback on FSH and LH), and maintenance of secondary sexual characteristics.
Synthetic nonsteroidal estrogen that binds to estrogen receptors (ERα/ERβ), activating estrogen-responsive gene transcription, leading to proliferation of estrogen-sensitive tissues.
1 to 5 mg intramuscularly every 3 to 4 weeks for estrogen replacement therapy.
0.5-2 mg orally once daily for palliative treatment of advanced prostate cancer; 5-15 mg orally once daily for prevention of postpartum breast engorgement.
None Documented
None Documented
Clinical Note
moderateDiethylstilbestrol + Digoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDiethylstilbestrol + Digitoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDiethylstilbestrol + Deslanoside
"Diethylstilbestrol may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDiethylstilbestrol + Acetyldigitoxin
The terminal elimination half-life of estradiol after intramuscular injection of Depo-Estradiol is approximately 5-9 days, reflecting slow release from the depot and prolonged systemic exposure.
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) in adults; prolonged in hepatic impairment.
Estradiol is extensively metabolized in the liver, with conjugated metabolites (glucuronides and sulfates) primarily excreted in urine (about 90%) and feces (about 10%). Less than 5% is excreted unchanged.
Primarily renal (90% as glucuronide and sulfate conjugates), with less than 5% excreted unchanged in urine; biliary/fecal elimination accounts for about 10%.
Category D/X
Category C
Estrogen
Estrogen
"Diethylstilbestrol may decrease the cardiotoxic activities of Acetyldigitoxin."